Claims
- 1. A method for inhibiting cancerous cell proliferation comprising the steps of:
selecting a composition containing 2-methoxyestradiol, the 2-ethyl-17-β-estradiol molecules identified as analogues 20-22 in FIG. 8, the 17-α-ethynyl molecules identified as analogues 23-26 in FIG. 8, the 17-α-ethyl molecules identified as analogues 27-30 in FIG. 8, the 2,3-methylenedioxy molecules identified as analogues 31, 32, and 33 in FIG. 9, the 2-alkoxy substituted analogues of estrone molecules identified as analogues 8-10 in FIG. 6, the 2-ethyl substituted molecule identified as analogue 14 in FIG. 6, or the 2,3-methylenedioxyestrone molecule identified as analogue 18 in FIG. 7; and administering said composition to cells in which is identified suspected cancer cells.
- 2. The method of claim 1 wherein said suspected cancer cells are brain cancer cells.
- 3. The method of claim 1 wherein said suspected cancer cells are nervous system cancer cells.
- 4. The method of claim 1 wherein said suspected cancer cells are brain cancer cells and nervous system cancer cells.
- 5. A method for inhibiting cancerous cell proliferation comprising the steps of:
selecting a composition consisting substantially of one or more of 2-methoxyestradiol, 2-ethoxyestradiol, 2-butoxyestradiol, 17-α″-ethynylestradiol with methoxy group at position 2, 17-″α-ethynylestradiol with butoxy group at position 2, 17-α″-ethynyl-9-α″-fluoroestradiol with methoxy group at position 2; and 17-α″-ethynyl-9-″α-fluoroestradiol with butoxy group at position 2; and administering said composition to cells in which is identified suspected cancer cells.
- 5. The method of claim 5 wherein said suspected cancer cells are brain cancer cells.
- 6. The method of claim 5 wherein said suspected cancer cells are nervous system cancer cells.
- 7. The method of claim 5 wherein said suspected cancer cells are brain cancer cells and nervous system cancer cells.
- 8. A composition for application to cancerous cells consisting in active constituents substantially of one or more agents chosen from a group consisting of 2-methoxyestradiol, 2-ethoxyestradiol, 2-butoxyestradiol, 17-α″-ethynylestradiol with methoxy group at position 2, 17-″α-ethynylestradiol with butoxy group at position 2, 17-α″-ethynyl-9-α″-fluoroestradiol with methoxy group at position 2, and 17-α″-ethynyl-9-″α-fluoroestradiol with butoxy group at position 2, 2-ethyl-17-β-estradiol molecules identified as analogues 20-22 in FIG. 8, the 17-α-ethynyl molecules identified as analogues 23-26 in FIG. 8, the 17-α-ethyl molecules identified as analogues 27-30 in FIG. 8, the 2,3-methylenedioxy molecules identified as analogues 31, 32, and 33 in FIG. 9, the 2-alkoxy substituted analogues of estrone molecules identified as analogues 8-10 in FIG. 6, the 2-ethyl substituted molecule identified as analogue 14 in FIG. 6, or the 2,3-methylenedioxyestrone molecule identified as analogue 18 in FIG. 7.
- 9. The method of claim 8 wherein said suspected cancer cells are brain cancer cells.
- 10. The method of claim 8 wherein said suspected cancer cells are nervous system cancer cells.
- 11. The method of claim 8 wherein said suspected cancer cells are brain cancer cells and nervous system cancer cells.
CITATION TO PRIOR APPLICATION
[0001] This is a continuation-in-part with respect to U.S. application, Ser. No. 09/527283, filed Mar. 17, 2000 from which priority is claimed under 35 U.S.C. §120 and under provisions of the Patent Cooperation Treaty. This is also a continuation-in-part with respect to that prior application (filed Feb. 5, 2001—no serial number yet available) which also claims priority of Ser. No. 09/527283.
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09527283 |
Mar 2000 |
US |
Child |
09777559 |
Feb 2001 |
US |
Parent |
09777151 |
Feb 2001 |
US |
Child |
09527283 |
Mar 2000 |
US |